Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Perrone

Showing results (101-110 of 112) with videos related to

Pageof 12
Sort By:
Frontiers in Oncology|May 21, 2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast CancerTomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, et al.
Journal of Endourology|February 16, 2026
Hugo<sup>TM</sup> RAS <i>vs</i> Da Vinci® Xi Robot-Assisted Partial Nephrectomy: First Propensity Score-Matched Comparison of Perioperative and Functional OutcomesFrancesco Prata, Riccardo Mastroianni, Giuseppe Simone, et al.
Tumori|September 20, 2023
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian surveyBruna Cerbelli, Alessio Cirillo, Giulia Pomati, et al.
Breast Cancer Research : BCR|May 14, 2025
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapyKonstantinos Venetis, Giulia Cursano, Roberta Scafetta, et al.
JAMA Oncology|December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung CancerMehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
NPJ Breast Cancer|January 5, 2021
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 17, 2026
Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP)Paola Parente, Federica Grillo, Matilde Callegarin, et al.
Oncotarget|April 21, 2017
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancerAranzazu Fernandez-Martinez, Tomás Pascual, Giuseppe Perrone, et al.
The Journal of Liquid Biopsy|August 12, 2025
Harmonization trial on <i>ESR1</i> testing strategies in ER+/HER2- breast cancer patients: an Italian experienceFrancesco Pepe, Gianluca Russo, Konstantinos Venetis, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 27, 2026
Integrated mutational landscape analysis of endometrial stromal sarcomaTobias M P Hartwich, Seungji Choi, Ayoung Hwang, et al.
Pageof 12

Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Frontiers in Oncology|May 21, 2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast CancerTomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, et al.
Journal of Endourology|February 16, 2026
Hugo<sup>TM</sup> RAS <i>vs</i> Da Vinci® Xi Robot-Assisted Partial Nephrectomy: First Propensity Score-Matched Comparison of Perioperative and Functional OutcomesFrancesco Prata, Riccardo Mastroianni, Giuseppe Simone, et al.
Tumori|September 20, 2023
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian surveyBruna Cerbelli, Alessio Cirillo, Giulia Pomati, et al.
Breast Cancer Research : BCR|May 14, 2025
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapyKonstantinos Venetis, Giulia Cursano, Roberta Scafetta, et al.
JAMA Oncology|December 26, 2024
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung CancerMehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, et al.
NPJ Breast Cancer|January 5, 2021
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancerFrancesco Schettini, Nuria Chic, Fara Brasó-Maristany, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 17, 2026
Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP)Paola Parente, Federica Grillo, Matilde Callegarin, et al.
Oncotarget|April 21, 2017
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancerAranzazu Fernandez-Martinez, Tomás Pascual, Giuseppe Perrone, et al.
The Journal of Liquid Biopsy|August 12, 2025
Harmonization trial on <i>ESR1</i> testing strategies in ER+/HER2- breast cancer patients: an Italian experienceFrancesco Pepe, Gianluca Russo, Konstantinos Venetis, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 27, 2026
Integrated mutational landscape analysis of endometrial stromal sarcomaTobias M P Hartwich, Seungji Choi, Ayoung Hwang, et al.
Pageof 12